http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111471104-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2469-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-08 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-10 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 |
filingDate | 2020-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2022-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2022-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-111471104-B |
titleOfInvention | PRRSV (porcine reproductive and respiratory syndrome virus) broad-spectrum neutralizing monoclonal antibody and application thereof |
abstract | The invention adopts PRRSV virus liquid-SD 16 as immunogen to immunize Balb/c mice. After cell fusion and virus infection, Marc145 cells are screened and cloned to obtain a positive hybridoma cell line which efficiently secretes the monoclonal antibody, and a mouse monoclonal antibody MAB-GP3 is obtained. The subtype of the monoclonal antibody MAB-GP3 is determined to be the monoclonal antibody IgG2b by ELISA technology. The PRRSV-I type and PRRSV-II type viruses infect Marc145 cells, and the monoclonal antibody is used for detection by using an IFA technology, so that the monoclonal antibody MAB-GP3 is proved to have broad-spectrum reactivity to the PRRSV-I and PRRSV-II type viruses. Then, the monoclonal antibody is used for virus neutralization experiments, and Western blot technology and qPCR technology are utilized to prove that the monoclonal antibody has neutralization activity on PRRSV-I and PRRSV-II viruses, so that virus invasion can be prevented, and an organism is protected from infection. |
priorityDate | 2020-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 515.